Compare
Citius Oncology, Inc. vs iBio, Inc. vs Minerva Neurosciences, Inc. vs Tenax Therapeutics, Inc.
| Latest fiscal year | Citius Oncology, Inc. CTOR | iBio, Inc. IBIO | Minerva Neurosciences, Inc. NERVRevenue covers only part of its income (partial revenue) | Tenax Therapeutics, Inc. TENX |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $100.0K | n/a | $0 |
| Revenue growth (YoY) | n/a | -75.0% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$24.76M | -$33.04M | -$293.42M | -$52.60M |
| EPS (Diluted) | -$0.34 | -$0.32 | -$34.67 | -$1.34 |
| Operating cash flow | -$5.49M | -$23.22M | -$13.51M | -$35.80M |
| Free cash flow | n/a | -$23.80M | n/a | n/a |
| Cash & equivalents | n/a | $56.40M | $82.30M | $97.60M |
| Total assets | $100.94M | $99.11M | $97.97M | $104.23M |
| Total liabilities | $56.08M | $13.40M | $233.76M | $7.16M |
| Shareholders' equity | $44.87M | $85.71M | -$140.75M | $97.07M |
| Return on year-end equity | -55.2% | -38.6% | n/a | -54.2% |
| Shares outstanding | 83.51M | 55.70M | 43.27M | 9.31M |
Revenue, most recent five fiscal years
| Fiscal year | Citius Oncology, Inc. | iBio, Inc. | Minerva Neurosciences, Inc. | Tenax Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $100.0K Ended 2026-06-30 | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $400.0K Ended 2025-06-30 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $225.0K Ended 2024-06-30 | n/a | n/a |
| 3 years earlier | n/a | $0 Ended 2023-06-30 | n/a | n/a |
| 4 years earlier | n/a | $1.88M Ended 2022-06-30 | n/a | n/a |